Pharmacovigilance Overview Quiz
10 Questions
0 Views

Pharmacovigilance Overview Quiz

Created by
@SweepingAntagonist

Questions and Answers

Which causality category indicates that an event has a plausible time relationship to drug intake?

  • Certain (correct)
  • Conditional/Unclassified
  • Probable/Likely
  • Unlikely
  • What aspect is NOT considered when assessing causality based on temporal relationships?

  • Event onset date
  • Date of therapy start
  • Therapy duration
  • Symptom severity (correct)
  • In which causality category is an adverse event classified if its relationship to the drug is improbable but not impossible?

  • Unassessable/Unclassifiable
  • Conditional/Unclassified
  • Unlikely (correct)
  • Possible
  • Which assessment criterion involves observing the effects after stopping and starting a medication?

    <p>Rechallenge</p> Signup and view all the answers

    What is a key consideration in the 'Unassessable/Unclassifiable' category?

    <p>Lack of plausible evidence</p> Signup and view all the answers

    Which of the following is NOT considered an alternative causality factor for an adverse event?

    <p>Symptom management techniques</p> Signup and view all the answers

    Which causality category is characterized by a reasonable time relationship to drug intake but lacks definitive evidence?

    <p>Possible</p> Signup and view all the answers

    In assessing causality, what does the term 'Dechallenge' refer to?

    <p>Stopping a drug to observe effects</p> Signup and view all the answers

    What is the primary focus of the assessment criterion known as 'Abnormal Laboratory tests'?

    <p>Identifying unusual or abnormal test results</p> Signup and view all the answers

    Which of the following is NOT a category within the WHO-UMC causality categories?

    <p>Improbable</p> Signup and view all the answers

    Study Notes

    Pharmacovigilance Overview

    • Pharmacovigilance covers various products including medicines, herbal supplements, biologics, blood products, vaccines, medical devices, cosmetics, veterinary products, and tobacco-related issues.

    Current Practices in Pharmacovigilance

    • Reporting Mechanism: Success relies heavily on reporting suspected adverse reactions (ADRs).
    • Spontaneous Reporting: Involves voluntary submission of ADR reports by healthcare professionals and pharmaceutical companies to national centers.
    • Active Surveillance Systems: Examples include Prescription Event Monitoring (PEM) in New Zealand and the UK, record linkage, and case-control studies.
    • National Pharmacovigilance Centers: Tasked with promoting ADR reporting, collecting and evaluating case reports, analyzing trends, and informing stakeholders of new risks.
    • WHO Program: Acts as a communication hub for international drug safety information and training.

    Regulatory Aspects and Guidelines

    • Company Core Data Sheet (CCDS): Prepared by Marketing Authorization Holders (MAHs) detailing safety information and other product-related data.
    • Efficacy vs. Effectiveness: Efficacy pertains to drug performance in clinical trials; effectiveness refers to real-world performance.
    • Off-label Use: Refers to the use of medicines for purposes not approved in their authorized product information.

    Signal Management

    • Triage System: Categorizes potential ADR reports into non-serious, serious, or invalid cases.
    • Signal Types:
      • Confirmed signals indicate a causal link between a drug and an adverse event.
      • Refuted signals show no relationship after investigation.
      • Unconfirmed signals require further investigation.

    Marketing Authorization Holder (MAH)

    • Defined as any entity with marketing authorization from the European Medicines Agency (EMA) to sell medicinal products in EU member states.

    ICH Guidelines

    • Safety Guidelines (S): Focus on identifying potential risks (e.g., carcinogenicity).
    • Efficacy Guidelines (E): Concern clinical trial conduct and reporting.
    • Multidisciplinary Guidelines (M): Address cross-cutting topics like medical terminology and technical documents.

    CIOMS and International Collaboration

    • Established by WHO and UNESCO in 1949 to improve pharmacovigilance and standardize ADR reporting internationally.
    • CIOMS launched its first Working Group on pharmacovigilance in 1986.

    Good Pharmacovigilance Practices (GVP)

    • GVP includes multiple modules addressing various aspects of pharmacovigilance such as systems quality, risk management, signal management, and safety communications.

    Individual Case Safety Report (ICSR)

    • A standardized document for reporting one or several suspected ADRs occurring in a single patient at a specific time.

    WHO-UMC Causality Categories

    • Categories: Certain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified, Unassessable/Unclassifiable.
    • Assessment Criteria:
      • Temporal relationship between drug administration and adverse event onset.
      • Abnormal lab test results that cannot be disregarded as related to the drug.
      • Outcomes of dechallenge and rechallenge tests.

    Factors Affecting Adverse Event Attribution

    • Medical Conditions: Pre-existing health issues may contribute to adverse events.
    • Concomitant Medications: Other drugs being taken can also play a role in adverse reactions.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    Test your knowledge on the various products covered by pharmacovigilance, including medicines, biotics, and vaccines. This quiz also explores current practices in pharmacovigilance and the factors influencing its success. Prepare to enhance your understanding in this critical area of healthcare.

    More Quizzes Like This

    Use Quizgecko on...
    Browser
    Browser